Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1)

Inclusion Criteria: 1. Refractory/relapsed B-NHL (including malignant transformation like Richter's transformation) with no available approved standard therapy. Including, but not restricted to: 1. Diffuse large B cell lymphoma (DLBCL): relapsed/refractory disease after ASCT or ineligible for ASCT after first-line therapy; transformation from CLL, SLL or FL allowed 2. Follicular lymphoma: at least 2 prior regimens and progression \<2 years after most recent line of therapy 3. Mantle cell lymphoma: beyond 1st CR with relapsed disease, progressive disease during first-line rituximab chemotherapy, or persistent disease after first-line rituximab-chemotherapy and not eligible or appropriate for conventional therapy, ASCT or relapsed after prior autologous SCT, prior therapies including ibrutinib if not contraindicated 4. CLL and SLL: after at least two lines of treatment including btk inhibitor ibrutinib and bcl2 inhibitor venetoclax (if not contraindicated), patients must have been refractory to at least one of the substances Patients with criteria 1b-d will only be eligible for Part I, dose cohort 1. 2. Patients in cohort 1a must have histologically confirmed DLBCL and associated subtypes with relapse or refractory disease after first line chemo-immunotherapy and be ineligible for HSCT 3. Histologically confirmed DLBCL and associated subtypes, defined by WHO 2016 classification: * DLBCL not otherwise specified (NOS) * High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with DLBCL histology (DHL/THL) and FL3B * Aggressive B-cell lymphoma * T-cell/histocyte rich B-cell lymphoma * Primary mediastinal B-cell lymphoma * EBV+ DLBCL * Transformed lymphoma (e.g. transformed follicular or marginal zone lymphoma) 4. First line chemo-immunotherapy is defined as therapy containing the combination of CD20 targeted immunotherapy and cytotoxic chemotherapy. 5. Chemotherapy-refractory disease is defined as one or more of the following: * No response to first line of therapy * PD as best response to first line therapy regimen * SD as best response after 4 cycles of first line therapy * Disease progression or relapsed ≤12 months of first line therapy (must have biopsy proven recurrence in relapsed individuals) 6. Ineligibility for HSCT is defined as having ONE of the following criteria: * Age based on country-specific definition * Impaired pulmonary function (DLCO or FEV1 ≤60%) * Impaired cardiac function (LVEF \<50%) * Impaired renal function (CrCl \<60 mL/min) * Impaired hepatic function (AST/ALT \>3 x ULN, bilirubin \>1.5 x ULN or patient's baseline) In addition, all patients must fulfil the following criteria: 7. Age ≥18 years 8. Measurable disease according to Lugano criteria 9. CD19 or CD20 tumor expression is not required after first line chemo-immunotherapy. 1. Must have archival tissue available, if received CD19 targeted therapy or CD20 antibody, archival tissue must have been obtained subsequent to that therapy 2. Must have at least 10 unstained slides of tissue available 3. If archival tissue is not available, must be willing to undergo attempted repeat biopsy and fine needle Aspiration 10. If has history of CNS disease, then must have: 1. No signs or symptoms of CNS disease 2. No active disease on magnetic resonance imaging (MRI) 3. Absence of large cell lymphoma in cerebral spinal fluid (CSF) on cytospin preparation and flow cytometry, regardless of the number of white blood cells 11. If has history of cerebral vascular accident (CVA): 1. The CVA event must be \>12 months prior to leukapheresis 2. Any neurological deficits must be stable 12. Estimated life expectancy of \>3 months other than primary disease 13. No childbearing potential (i.e. postmenopausal, absence of menstrual bleeding for at least 1 year), hysterectomy, bilateral ovariectomy or tubal section/ligation) or negative pregnancy test at screening and before chemotherapy in women of childbearing potential. Sexually active female patients of childbearing potential should use one of the following highly effective methods of contraception (Pearl index \<1%): hormonal contraceptives (oral, injected, implanted, transdermal), intrauterine devices or systems (e.g. hormonal and non-hormonal IUD), or vasectomized sexual partner for at least 1 month before the trial start, during the trial and in the 6 months following dosing. Male patients, unless surgically sterile (meaning at least two consecutive analyses following vasectomy demonstrate absence of sperms in the ejaculate), must be using two acceptable methods for contraception (e.g. spermicide and condom) during the trial and refrain from fathering a child throughout the trial and for up to 12 months after dosing 14. Signed and dated informed consent before conduct of any trial-specific procedure Exclusion Criteria: 1. Eastern Cooperative Oncology Group (ECOG) performance status \>2 2. Absolute neutrophil count (ANC) \<1,000/µL 3. Platelet count \<50,000/µL 4. Absolute lymphocyte count \<100/µL 5. Presence of leukemia/lymphoma cells in peripheral blood 6. Primary CNS lymphoma 7. Unable to give informed consent 8. Known history of infection with human immunodeficiency virus (HIV) or active infection with hepatitis B (HGsAg positive) 9. Known history of infection with hepatitis C virus unless treated and confirmed to be polymerase chain reaction (PCR) negative 10. Known history or presence of seizure activities or on active anti-seizure medications within the previous 12 months 11. Known history of CVA within prior 12 months 12. Known history or presence of autoimmune CNS disease, such as multiple sclerosis, optic neuritis or other immunologic or inflammatory disease 13. Presence of CNS disease that, in the judgment of the investigator, may impair the ability to evaluate neurotoxicity 14. Active systemic fungal, viral or bacterial infection 15. Clinical heart failure with New York Heart Association class ≥2 or LVEF \<30% 16. Resting oxygen saturation \<90% on room air 17. Liver dysfunction as indicated by total bilirubin, AST and/or ALT \>5 x institutional ULN, unless directly attributable to patient's tumor 18. CrCl \<30 mL/min calculated according to the modified formula of Cockcroft and Gault or by direct urine collection 19. Pregnant or breast-feeding woman 20. Active secondary malignancy requiring treatment 21. Medical condition requiring prolonged use of systemic corticosteroids \>10 mg/day 22. Concurrent radiotherapy (allow up to time of leukapheresis) 23. Baseline dementia that would interfere with therapy or monitoring, determined using mini-mental status exam at baseline 24. History of severe immediate hypersensitivity reaction against any drug or its ingredients/impurities that is scheduled to be given during trial participation e.g. as part of the mandatory lymphodepletion protocol, premedication for infusion, or rescue medication/salvage therapies for treatment related toxicities 25. Patients in which such medication (see exclusion criterion 24) is contraindicated for other reasons than hypersensitivity (e.g. live vaccines and fludarabine) 26. Refusal to participate in CAR-T long-term follow-up (LTFU). 27. Refusal to undergo core needle biopsy or fine needle aspiration of tumor on day 2-5 after MB-CART infusion and at time of disease progression and relapse